Sexually Transmitted Diseases (STD) Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Instruments And Services, Consumables, Software), By Application (HIV Testing, HSV Testing, CT/NG Testing, Syphilis Testing, Gonorrhea Testing, Others), By Technology (Immunoassay, Molecular Diagnostics, Other), By Location Of Testing (Laboratory Testing, Point Of Care Testing, Others), By Region & Competition, 2021-2031F
The Global Sexually Transmitted Diseases (STD) Diagnostics Market is projected to expand from USD 103.07 Billion in 2025 to USD 151.33 Billion by 2031, reflecting a compound annual growth rate (CAGR) of 6.61%. This sector comprises reagents, instruments, and consumables specifically designed to identify pathogens causing infections such as Syphilis, Gonorrhea, and Chlamydia. The market's growth is primarily driven by the rising global prevalence of these infections and the rollout of government initiatives that encourage routine screening to support early intervention and effective treatment.
According to 2025 surveillance data referenced by the American Sexual Health Association, the total number of reported sexually transmitted infections remained 13% higher than levels recorded ten years prior. While this elevated burden fuels demand, the market faces a significant obstacle due to the social stigma surrounding testing. This stigma often discourages individuals from accessing necessary diagnostic services, thereby impeding broader market penetration and adoption.
Market Driver
The escalating global incidence of sexually transmitted infections acts as a fundamental catalyst for market growth, necessitating a robust testing infrastructure to control outbreaks and prevent long-term complications. The resurgence of bacterial infections, especially in developed regions, compels healthcare systems to acquire increased volumes of molecular and immunoassay-based diagnostic consumables to manage the growing patient load. For instance, the UK Health Security Agency's June 2025 report noted that early-stage syphilis diagnoses in England reached 9,535 cases in 2024, a 2% annual increase, while provisional CDC data from 2025 indicated over 2.2 million total cases of chlamydia, gonorrhea, and syphilis in the United States for the 2024 surveillance period, reinforcing the sustained high demand for diagnostics.
Simultaneously, increasing consumer adoption of at-home and self-collection testing kits is reshaping the diagnostic landscape by decentralizing care and bypassing barriers such as clinical stigma and scheduling logistics. This shift is enabled by regulatory approvals of over-the-counter molecular platforms that provide lab-quality accuracy in private settings. As reported by the FDA in March 2025, the newly authorized Visby Medical Women's Sexual Health Test demonstrated 97.2% accuracy for Chlamydia trachomatis during validation. The availability of high-performance self-tests encourages frequent screening among younger demographics, driving revenue for direct-to-consumer manufacturers and alleviating operational pressure on sexual health clinics.
Market Challenge
Social stigma regarding sexually transmitted diseases constitutes a major restraint on the global diagnostics market by discouraging individuals from seeking timely screening. This psychological barrier, rooted in fear of judgment, embarrassment, or privacy concerns, creates a strong reluctance to visit clinics or utilize testing services. Consequently, a substantial portion of the at-risk population avoids necessary testing, which directly reduces the consumption of diagnostic tests, reagents, and consumables in clinical settings, thereby limiting the addressable market size and restricting revenue generation for manufacturers.
The consequence of this testing gap is highlighted by the disparity between infection estimates and actual diagnostic uptake. According to the World Health Organization, in 2024, more than 1 million sexually transmitted infections were acquired daily worldwide, yet a vast number of these cases remained undiagnosed. This data indicates that despite the availability of testing platforms, the market cannot fully capitalize on the rising prevalence of infections because social apprehension effectively blocks patient entry into the diagnostic ecosystem.
Market Trends
The transition toward Multiplex Nucleic Acid Amplification Tests (NAATs) is fundamentally changing clinical workflows by enabling the simultaneous detection of multiple pathogens from a single patient specimen. This shift toward syndromic panel testing addresses high rates of co-infections, such as chlamydia presenting with gonorrhea, which single-target assays often miss. By consolidating testing into one run, laboratories can reduce turnaround times and operational costs while ensuring comprehensive diagnosis, driving commercial adoption. For example, Hologic, Inc. reported a 9.4% increase in molecular diagnostics revenue in November 2024, largely driven by elevated sales of their multiplex assay for bacterial vaginosis, Candida vaginitis, and Trichomonas vaginalis.
Concurrently, the implementation of Next-Generation Sequencing for genomic surveillance is gaining momentum to combat the escalating threat of antimicrobial resistance in sexually transmitted pathogens. Unlike traditional diagnostics, genomic sequencing allows public health entities to identify specific resistance mutations and track transmission clusters, particularly for Neisseria gonorrhoeae. This capability is essential for tailoring treatment protocols, as highlighted by a November 2025 World Health Organization release which noted that resistance to ceftriaxone and cefixime rose to 5% and 11% respectively between 2022 and 2024, necessitating advanced genomic profiling to manage these resistant strains.
Key Market Players
In this report, the Global Sexually Transmitted Diseases (STD) Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Sexually Transmitted Diseases (STD) Diagnostics Market.
Available Customizations:
Global Sexually Transmitted Diseases (STD) Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
According to 2025 surveillance data referenced by the American Sexual Health Association, the total number of reported sexually transmitted infections remained 13% higher than levels recorded ten years prior. While this elevated burden fuels demand, the market faces a significant obstacle due to the social stigma surrounding testing. This stigma often discourages individuals from accessing necessary diagnostic services, thereby impeding broader market penetration and adoption.
Market Driver
The escalating global incidence of sexually transmitted infections acts as a fundamental catalyst for market growth, necessitating a robust testing infrastructure to control outbreaks and prevent long-term complications. The resurgence of bacterial infections, especially in developed regions, compels healthcare systems to acquire increased volumes of molecular and immunoassay-based diagnostic consumables to manage the growing patient load. For instance, the UK Health Security Agency's June 2025 report noted that early-stage syphilis diagnoses in England reached 9,535 cases in 2024, a 2% annual increase, while provisional CDC data from 2025 indicated over 2.2 million total cases of chlamydia, gonorrhea, and syphilis in the United States for the 2024 surveillance period, reinforcing the sustained high demand for diagnostics.
Simultaneously, increasing consumer adoption of at-home and self-collection testing kits is reshaping the diagnostic landscape by decentralizing care and bypassing barriers such as clinical stigma and scheduling logistics. This shift is enabled by regulatory approvals of over-the-counter molecular platforms that provide lab-quality accuracy in private settings. As reported by the FDA in March 2025, the newly authorized Visby Medical Women's Sexual Health Test demonstrated 97.2% accuracy for Chlamydia trachomatis during validation. The availability of high-performance self-tests encourages frequent screening among younger demographics, driving revenue for direct-to-consumer manufacturers and alleviating operational pressure on sexual health clinics.
Market Challenge
Social stigma regarding sexually transmitted diseases constitutes a major restraint on the global diagnostics market by discouraging individuals from seeking timely screening. This psychological barrier, rooted in fear of judgment, embarrassment, or privacy concerns, creates a strong reluctance to visit clinics or utilize testing services. Consequently, a substantial portion of the at-risk population avoids necessary testing, which directly reduces the consumption of diagnostic tests, reagents, and consumables in clinical settings, thereby limiting the addressable market size and restricting revenue generation for manufacturers.
The consequence of this testing gap is highlighted by the disparity between infection estimates and actual diagnostic uptake. According to the World Health Organization, in 2024, more than 1 million sexually transmitted infections were acquired daily worldwide, yet a vast number of these cases remained undiagnosed. This data indicates that despite the availability of testing platforms, the market cannot fully capitalize on the rising prevalence of infections because social apprehension effectively blocks patient entry into the diagnostic ecosystem.
Market Trends
The transition toward Multiplex Nucleic Acid Amplification Tests (NAATs) is fundamentally changing clinical workflows by enabling the simultaneous detection of multiple pathogens from a single patient specimen. This shift toward syndromic panel testing addresses high rates of co-infections, such as chlamydia presenting with gonorrhea, which single-target assays often miss. By consolidating testing into one run, laboratories can reduce turnaround times and operational costs while ensuring comprehensive diagnosis, driving commercial adoption. For example, Hologic, Inc. reported a 9.4% increase in molecular diagnostics revenue in November 2024, largely driven by elevated sales of their multiplex assay for bacterial vaginosis, Candida vaginitis, and Trichomonas vaginalis.
Concurrently, the implementation of Next-Generation Sequencing for genomic surveillance is gaining momentum to combat the escalating threat of antimicrobial resistance in sexually transmitted pathogens. Unlike traditional diagnostics, genomic sequencing allows public health entities to identify specific resistance mutations and track transmission clusters, particularly for Neisseria gonorrhoeae. This capability is essential for tailoring treatment protocols, as highlighted by a November 2025 World Health Organization release which noted that resistance to ceftriaxone and cefixime rose to 5% and 11% respectively between 2022 and 2024, necessitating advanced genomic profiling to manage these resistant strains.
Key Market Players
- Becton Dickinson and Company
- F. Hoffmann-La Roche Ltd.
- Hologic, Inc.
- bioMerieux S.A.
- Abbott Laboratories Inc.
- Danaher Corporation
- Qiagen N.V.
- Thermo Fisher Scientific Inc.
- DiaSorin S.p.A
- Bio-Rad Laboratories, Inc.
In this report, the Global Sexually Transmitted Diseases (STD) Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Sexually Transmitted Diseases (STD) Diagnostics Market, By Product
- Instruments And Services
- Consumables
- Software
- Sexually Transmitted Diseases (STD) Diagnostics Market, By Application
- HIV Testing
- HSV Testing
- CT/NG Testing
- Syphilis Testing
- Gonorrhea Testing
- Others
- Sexually Transmitted Diseases (STD) Diagnostics Market, By Technology
- Immunoassay
- Molecular Diagnostics
- Other
- Sexually Transmitted Diseases (STD) Diagnostics Market, By Location Of Testing
- Laboratory Testing
- Point Of Care Testing
- Others
- Sexually Transmitted Diseases (STD) Diagnostics Market, By Region
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies present in the Global Sexually Transmitted Diseases (STD) Diagnostics Market.
Available Customizations:
Global Sexually Transmitted Diseases (STD) Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL SEXUALLY TRANSMITTED DISEASES (STD) DIAGNOSTICS MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product (Instruments And Services, Consumables, Software)
5.2.2. By Application (HIV Testing, HSV Testing, CT/NG Testing, Syphilis Testing, Gonorrhea Testing, Others)
5.2.3. By Technology (Immunoassay, Molecular Diagnostics, Other)
5.2.4. By Location Of Testing (Laboratory Testing, Point Of Care Testing, Others)
5.2.5. By Region
5.2.6. By Company (2025)
5.3. Market Map
6. NORTH AMERICA SEXUALLY TRANSMITTED DISEASES (STD) DIAGNOSTICS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product
6.2.2. By Application
6.2.3. By Technology
6.2.4. By Location Of Testing
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Product
6.3.1.2.2. By Application
6.3.1.2.3. By Technology
6.3.1.2.4. By Location Of Testing
6.3.2. Canada Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Product
6.3.2.2.2. By Application
6.3.2.2.3. By Technology
6.3.2.2.4. By Location Of Testing
6.3.3. Mexico Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Product
6.3.3.2.2. By Application
6.3.3.2.3. By Technology
6.3.3.2.4. By Location Of Testing
7. EUROPE SEXUALLY TRANSMITTED DISEASES (STD) DIAGNOSTICS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product
7.2.2. By Application
7.2.3. By Technology
7.2.4. By Location Of Testing
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Product
7.3.1.2.2. By Application
7.3.1.2.3. By Technology
7.3.1.2.4. By Location Of Testing
7.3.2. France Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Product
7.3.2.2.2. By Application
7.3.2.2.3. By Technology
7.3.2.2.4. By Location Of Testing
7.3.3. United Kingdom Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Product
7.3.3.2.2. By Application
7.3.3.2.3. By Technology
7.3.3.2.4. By Location Of Testing
7.3.4. Italy Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Product
7.3.4.2.2. By Application
7.3.4.2.3. By Technology
7.3.4.2.4. By Location Of Testing
7.3.5. Spain Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Product
7.3.5.2.2. By Application
7.3.5.2.3. By Technology
7.3.5.2.4. By Location Of Testing
8. ASIA PACIFIC SEXUALLY TRANSMITTED DISEASES (STD) DIAGNOSTICS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product
8.2.2. By Application
8.2.3. By Technology
8.2.4. By Location Of Testing
8.2.5. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Product
8.3.1.2.2. By Application
8.3.1.2.3. By Technology
8.3.1.2.4. By Location Of Testing
8.3.2. India Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Product
8.3.2.2.2. By Application
8.3.2.2.3. By Technology
8.3.2.2.4. By Location Of Testing
8.3.3. Japan Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Product
8.3.3.2.2. By Application
8.3.3.2.3. By Technology
8.3.3.2.4. By Location Of Testing
8.3.4. South Korea Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Product
8.3.4.2.2. By Application
8.3.4.2.3. By Technology
8.3.4.2.4. By Location Of Testing
8.3.5. Australia Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Product
8.3.5.2.2. By Application
8.3.5.2.3. By Technology
8.3.5.2.4. By Location Of Testing
9. MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASES (STD) DIAGNOSTICS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product
9.2.2. By Application
9.2.3. By Technology
9.2.4. By Location Of Testing
9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Product
9.3.1.2.2. By Application
9.3.1.2.3. By Technology
9.3.1.2.4. By Location Of Testing
9.3.2. UAE Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Product
9.3.2.2.2. By Application
9.3.2.2.3. By Technology
9.3.2.2.4. By Location Of Testing
9.3.3. South Africa Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Product
9.3.3.2.2. By Application
9.3.3.2.3. By Technology
9.3.3.2.4. By Location Of Testing
10. SOUTH AMERICA SEXUALLY TRANSMITTED DISEASES (STD) DIAGNOSTICS MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Product
10.2.2. By Application
10.2.3. By Technology
10.2.4. By Location Of Testing
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Product
10.3.1.2.2. By Application
10.3.1.2.3. By Technology
10.3.1.2.4. By Location Of Testing
10.3.2. Colombia Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Product
10.3.2.2.2. By Application
10.3.2.2.3. By Technology
10.3.2.2.4. By Location Of Testing
10.3.3. Argentina Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Product
10.3.3.2.2. By Application
10.3.3.2.3. By Technology
10.3.3.2.4. By Location Of Testing
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. GLOBAL SEXUALLY TRANSMITTED DISEASES (STD) DIAGNOSTICS MARKET: SWOT ANALYSIS
14. PORTER'S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. Becton Dickinson and Company
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. F. Hoffmann-La Roche Ltd.
15.3. Hologic, Inc.
15.4. bioMerieux S.A.
15.5. Abbott Laboratories Inc.
15.6. Danaher Corporation
15.7. Qiagen N.V.
15.8. Thermo Fisher Scientific Inc.
15.9. DiaSorin S.p.A
15.10. Bio-Rad Laboratories, Inc.
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL SEXUALLY TRANSMITTED DISEASES (STD) DIAGNOSTICS MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product (Instruments And Services, Consumables, Software)
5.2.2. By Application (HIV Testing, HSV Testing, CT/NG Testing, Syphilis Testing, Gonorrhea Testing, Others)
5.2.3. By Technology (Immunoassay, Molecular Diagnostics, Other)
5.2.4. By Location Of Testing (Laboratory Testing, Point Of Care Testing, Others)
5.2.5. By Region
5.2.6. By Company (2025)
5.3. Market Map
6. NORTH AMERICA SEXUALLY TRANSMITTED DISEASES (STD) DIAGNOSTICS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product
6.2.2. By Application
6.2.3. By Technology
6.2.4. By Location Of Testing
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Product
6.3.1.2.2. By Application
6.3.1.2.3. By Technology
6.3.1.2.4. By Location Of Testing
6.3.2. Canada Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Product
6.3.2.2.2. By Application
6.3.2.2.3. By Technology
6.3.2.2.4. By Location Of Testing
6.3.3. Mexico Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Product
6.3.3.2.2. By Application
6.3.3.2.3. By Technology
6.3.3.2.4. By Location Of Testing
7. EUROPE SEXUALLY TRANSMITTED DISEASES (STD) DIAGNOSTICS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product
7.2.2. By Application
7.2.3. By Technology
7.2.4. By Location Of Testing
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Product
7.3.1.2.2. By Application
7.3.1.2.3. By Technology
7.3.1.2.4. By Location Of Testing
7.3.2. France Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Product
7.3.2.2.2. By Application
7.3.2.2.3. By Technology
7.3.2.2.4. By Location Of Testing
7.3.3. United Kingdom Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Product
7.3.3.2.2. By Application
7.3.3.2.3. By Technology
7.3.3.2.4. By Location Of Testing
7.3.4. Italy Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Product
7.3.4.2.2. By Application
7.3.4.2.3. By Technology
7.3.4.2.4. By Location Of Testing
7.3.5. Spain Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Product
7.3.5.2.2. By Application
7.3.5.2.3. By Technology
7.3.5.2.4. By Location Of Testing
8. ASIA PACIFIC SEXUALLY TRANSMITTED DISEASES (STD) DIAGNOSTICS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product
8.2.2. By Application
8.2.3. By Technology
8.2.4. By Location Of Testing
8.2.5. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Product
8.3.1.2.2. By Application
8.3.1.2.3. By Technology
8.3.1.2.4. By Location Of Testing
8.3.2. India Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Product
8.3.2.2.2. By Application
8.3.2.2.3. By Technology
8.3.2.2.4. By Location Of Testing
8.3.3. Japan Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Product
8.3.3.2.2. By Application
8.3.3.2.3. By Technology
8.3.3.2.4. By Location Of Testing
8.3.4. South Korea Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Product
8.3.4.2.2. By Application
8.3.4.2.3. By Technology
8.3.4.2.4. By Location Of Testing
8.3.5. Australia Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Product
8.3.5.2.2. By Application
8.3.5.2.3. By Technology
8.3.5.2.4. By Location Of Testing
9. MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASES (STD) DIAGNOSTICS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product
9.2.2. By Application
9.2.3. By Technology
9.2.4. By Location Of Testing
9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Product
9.3.1.2.2. By Application
9.3.1.2.3. By Technology
9.3.1.2.4. By Location Of Testing
9.3.2. UAE Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Product
9.3.2.2.2. By Application
9.3.2.2.3. By Technology
9.3.2.2.4. By Location Of Testing
9.3.3. South Africa Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Product
9.3.3.2.2. By Application
9.3.3.2.3. By Technology
9.3.3.2.4. By Location Of Testing
10. SOUTH AMERICA SEXUALLY TRANSMITTED DISEASES (STD) DIAGNOSTICS MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Product
10.2.2. By Application
10.2.3. By Technology
10.2.4. By Location Of Testing
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Product
10.3.1.2.2. By Application
10.3.1.2.3. By Technology
10.3.1.2.4. By Location Of Testing
10.3.2. Colombia Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Product
10.3.2.2.2. By Application
10.3.2.2.3. By Technology
10.3.2.2.4. By Location Of Testing
10.3.3. Argentina Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Product
10.3.3.2.2. By Application
10.3.3.2.3. By Technology
10.3.3.2.4. By Location Of Testing
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. GLOBAL SEXUALLY TRANSMITTED DISEASES (STD) DIAGNOSTICS MARKET: SWOT ANALYSIS
14. PORTER'S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. Becton Dickinson and Company
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. F. Hoffmann-La Roche Ltd.
15.3. Hologic, Inc.
15.4. bioMerieux S.A.
15.5. Abbott Laboratories Inc.
15.6. Danaher Corporation
15.7. Qiagen N.V.
15.8. Thermo Fisher Scientific Inc.
15.9. DiaSorin S.p.A
15.10. Bio-Rad Laboratories, Inc.
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
